TUR-Bt术后膀胱内灌注吡柔比星预防复发的临床观察

目的：探讨吡柔比星（THP）膀胱内灌注化疗预防浅表性膀胱癌TUR－Bt术后的效果和安全性。方法：选择44例TUR－Bt术后并有随访结果的病例，术后定期应用THP 30mg／30ml 1次／周，连续8周以后1次／月，连续8个月。膀胱内灌注化疗，每次膀胱内保留30分钟，根据随访结果对其疗效进行评价。结果：44例TUR－Bt术后患者均定期随访6～l2个月，无肿瘤复发，6例膀胱粘膜活检阳性的病例，也未见明确肿瘤生长。结论：吡柔比星对浅表性膀胱癌有明显的治疗和预防复发的作用，对膀胱内未见明确肿瘤，而膀胱粘膜活检阳性的病例亦有明显的治疗作用。

Low resolutation fluorotyping of HLA-DRBl locus

Objective To investigate and evaluate a novel fluorotyping procedure for HLA-DRB1 locus. Methods On the basis of low resolutation SSP technique, the fluorogenic probe was used to establish the fluorotyping procedure of HLA-DRB1 which was carried out for 46 samples. Results The fluorotyping has been sucessful for all the 46 samples and was completely coincident to the SSP results. As compared to the serological typing of DR locus,the coincidence rate was 66. 3% (61/92) whereas the coincidence rate of both the 2 specific genes was 43. 5% (20/46). Conclusion Fluorotyping is accurate, sensitve, reproducible, depends less on manual manipulation and eliminates the problems related to contamination. 10 refs.

荧光定量分型法在HLA-DRB1位点分型中的应用

目的 探讨荧光定量PCR(FQ PCR)分型方法在HLA分型中的应用价值。 方法 在低分辨SSP法基础上 ,加入荧光探针 ,建立HLA DR位点荧光定量分型法 ,对 46例标本进行分型。 结果 46例样本分型均成功。与SSP结果完全相同 ,与血清学分型结果比较 ,以DR位点单体型计算 ,符合率 66.3 % ( 61/ 92 ) ,两个等位基因型与血清学结果完全相符者 43 .5 % ( 2 0 / 46)。 结论 荧光定量分型法可提高自动化程度 ,减少污染机会 ,简化操作。与血清法相比 。